Clinical Relevance of Urokinase-Type Plasminogen Activator, Its Receptor, and Its Inhibitor Type 1 in Endometrial Cancer

By Tecimer C.   Doering D.L.   Goldsmith L.J.   Meyer J.S.   Abdulhay G.   Wittliff J.L.  

Gynecologic Oncology, Vol. 80, Iss. 1, 2001-01 ,pp. : 48-55

Elsevier

Access to resources Recommend Favorite

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients

By Chung Hyun   Rha Sun   Park Joon   Yoo Nae   Kim Joo   Roh Jae   Min Jin   Lee Kyong   Kim Byung   Kim Jin  

Breast Cancer Research and Treatment, Vol. 49, Iss. 1, 1998-05 ,pp. : 41-50

Springer Publishing Company

Access to resources Recommend Favorite

Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance

By          

Oncology Reports, Vol. 29, Iss. 2, 2013-01 ,pp. : 637-645

Spandidos Publications

Access to resources Recommend Favorite

Inhibition of Human Breast Cancer Cell Invasion by siRNA Against Urokinase-Type Plasminogen Activator

By Huang Hong-Yan   Jiang Ze-Fei   Li Qing-Xia   Liu Jia-Yun   Wang Tao   Zhang Rui   Zhao Jing   Xu Yan-Ming   Bao Wei   Zhang Yong   Jia Lin-Tao   Yang An-Gang  

Cancer Investigation, Vol. 28, Iss. 7, 2010-07 ,pp. : 689-697

Informa Healthcare

Access to resources Recommend Favorite

Downregulation of the urokinase-type plasminogen activator receptor through inhibition of translation by antisense oligonucleotide suppresses invasion of human glioblastoma cells

By Mohan Pamarthi   Lakka Sajani   Mohanam Sanjeeva   Kin Yoshiaki   Sawaya Raymond   Kyritsis Anthanassios   Nicolson Garth   Rao Jasti  

Clinical and Experimental Metastasis, Vol. 17, Iss. 7, 1999-09 ,pp. : 617-621

Springer Publishing Company

Access to resources Recommend Favorite